Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 16/20 | 0.72 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tabilautide SCHEMBL29711463 | 1.00 | NOD1 (0.72) | NOD1SLC6A5FAAHESR1PGR | |
| Pimelautide SCHEMBL444469 | 0.88 | NOD1 (0.65) | NOD1SLC6A5FAAHESR1PGR | |
| Pimelautide SCHEMBL28126753 | 0.88 | NOD1 (0.65) | NOD1SLC6A5FAAHESR1PGR | |
| SCHEMBL9785097 | 0.85 | NOD1 (0.71) | NOD1SLC6A5FAAH | |
| SCHEMBL29429305 | 0.85 | NOD1 (0.62) | NOD1SLC6A5FAAH | |
| SCHEMBL29429265 | 0.85 | NOD1 (0.62) | NOD1SLC6A5FAAH | |
| SCHEMBL11283421 | 0.85 | NOD1 (0.62) | NOD1SLC6A5FAAH | |
| SCHEMBL29675028 | 0.85 | NOD1 (0.62) | NOD1SLC6A5FAAH | |
| SCHEMBL29429263 | 0.85 | NOD1 (0.62) | NOD1SLC6A5FAAH | |
| SCHEMBL7934767 | 0.83 | NOD1 (0.82) | NOD1SLC6A5FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103313599-B | Substituted 4- (arylamino) selenophenopyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD. (IN) | 2016-03-23 | — | — | CN | claimed |
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014134005-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-08-28 | — | — | US | claimed |
| CN-101486668-B | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT INC | 2014-07-02 | — | — | CN | claimed |
| CN-103313599-A | Substituted 4- (arylamino) selenophenopyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD | 2013-09-18 | — | — | CN | claimed |
| CN-103221048-A | Substituted 4- (selenophen-2 (or 3) -ylamino) pyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD | 2013-07-24 | — | — | CN | claimed |
| US-8299291-B2 | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs | XENOPORT, INC. (US) | 2012-10-30 | — | — | US | claimed |
| US-8062870-B2 | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs | XENOPORT, INC. (US) | 2011-11-22 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | JACOB GARY S | 2006-05-18 | — | — | US | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-6515028-B1 | Used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| WO-2002018369-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | NOD1 872/4885SLC6A5 1421/4885FAAH 3294/4885 |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | NOD1 3872/4885SLC6A5 1024/4885FAAH 248/4885 |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | NOD1 3872/4885SLC6A5 1024/4885FAAH 248/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | NOD1 679/4885SLC6A5 105/4885FAAH 2036/4885 |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | HAVCR2, DERA, UGGT1 | NOD1 53/4885SLC6A5 1101/4885FAAH 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.